www.sciencedirect.com/science/arti...

Authors combined targeted NGS with STAS and LVI scoring and organ-specific metastasis profiling within a single well-defined NSCLC cohort. This design allows them to directly link #STK11 mutation subtypes with distinct clinical and metastatic phenotypes. #LKB1

Clinical data from lung adenocarcinoma patients with KRASG12C and #STK11 #LKB1 mutations were analyzed, looking for correlation between high squamous gene signature at baseline and response to adagrasib. Analysis reveals patients with a high squamous gene signature had poorer responses to treatment.

#LKB1 mutation (shown by green fluorescent protein) in lung cancer #metastasis. Beautiful image. Red = Actin. Cell nuclei in blue. 😍

Credit: National Cancer Institute / Winship Cancer Institute of Emory University / Science Photo Library @winshipatemory.bsky.social

#STK11

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer Up to one third of all breast cancers are classified as the aggressive HER2-positive subtype, which is associated with a higher risk of recurrence compared to HER2-negative breast cancers. The HER2 hy...

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer

If LKB1 is removed (or "knocked out"), the activation of #AMPK by PKA is significantly reduced. However, even without #LKB1 ( #STK11 ), there is still some activation of AMPK.

Clinical perspectives on the value of testing for STK11 and KEAP1 mutations in advanced NSCLC Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs)...

pmc.ncbi.nlm.nih.gov/articles/PMC...

#stk11 #lkb1

Insights into targeting LKB1 in tumorigenesis Genetic alterations to serine-threonine kinase 11 (STK11) have been implicated in Peutz-Jeghers syndrome and tumorigenesis. Further exploration of the…

"To improve the understanding of LKB1 in physiology and oncology, this review highlights the role of LKB1 in tumorigenesis and addresses the therapeutic relevancy of LKB1 inhibitors." #LKB1 #STK11

Dr Lacey Padron @ #Noetik another ex- #PICI talks on developing #Foundation Model to reconstruct #cancer #immunoprofiling / I expect image analysis will predict specific mutations for ex. #STK11 #Bridge2024 @sitcancer.bsky.social #AI #ML @microsoftcopilot.bsky.social #ChilesResearch #FINISHCANCER